搜索范围
A5762
应用筛选条件
关键词:'A5762'
显示 1-30 #N/A 95 条结果 关于 "A5762" 范围 论文
Fludarabine in paediatric steroid-refractory inflammatory lung injury after stem cell transplantation.
Martine F Raphael et al.
The European respiratory journal, 41(2), 479-483 (2013-02-02)
Maurizio Miano et al.
Journal of pediatric hematology/oncology, 36(3), e145-e148 (2013-04-17)
A 9-month-old boy with life-threatening multiresistant pure red cell anemia/autoimmune hemolytic anemia within the frame of a possible, undiagnosed immune-mediated disease was initially treated with prednisone. Further-line therapies of the following 7 relapses included immunoglobulins, rituximab, cyclophosphamide, and alentuzumab followed
Hamed Elgendy et al.
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 13 Suppl 1, 100-107 (2015-04-22)
The outcome of children who had living-donor liver transplant was analyzed according to their status before transplant, and we analyzed the outcome of critically ill patients. This was a retrospective analysis of children who received primary living-donor liver transplant at
Amandine Le Bourgeois et al.
European journal of haematology, 90(3), 177-186 (2013-01-11)
This retrospective analysis aimed to assess hematopoietic and immune recovery in a cohort of 53 patients [males: n = 33; median age: 59 yr (range: 22-70)] who received a FB2 (fludarabine 120-150 mg/m² + IV busulfan 6.4 mg/kg + antithymocyte
Peter Martin et al.
Cancer, 119(23), 4129-4136 (2013-09-06)
Drug choice and delivered dose of treatment potentially influence outcome in patients treated for follicular lymphoma (FL). Historically, observational studies have evaluated drug choice. The National LymphoCare Study (NLCS) is a prospective, observational study of patients with FL who were
S P Chantepie et al.
Leukemia research, 38(5), 569-574 (2014-03-25)
In reduced-toxicity conditioning hematopoietic stem cell transplantation, several studies failed to demonstrate the superiority of one conditioning over another. This study described 51 patients (median age of 58 years) allografted with the new FB3-ATG2 conditioning regimen for myeloid (66%) or
Johannes F Fahrmann et al.
Lipids in health and disease, 12, 36-36 (2013-03-19)
B-Cell chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the United States. Clinical treatment of CLL is often limited due to drug resistance and severe therapy-induced toxicities. We hypothesized that the omega 3 (n-3) fatty acids
Sho Yamazaki et al.
Internal medicine (Tokyo, Japan), 51(24), 3427-3430 (2012-12-22)
Fludarabine-based therapy is widely approved as a first-line treatment for chronic lymphocytic leukemia (CLL). This treatment is occasionally associated with prolonged myelosuppression. We herein describe the cases of CLL who underwent fludarabine, cyclophosphamide and rituximab (FCR) therapy. Bone marrow examinations
Antiviral drug vidarabine possessing cardiac type 5 adenylyl cyclase inhibitory property did not affect cardiohemodynamic or electrophysiological variables in the halothane-anesthetized dogs
Wada T, et al.
The Journal of Toxicological Sciences, 41(1), 115-122 (2016)
AMPK involvement in endoplasmic reticulum stress and autophagy modulation after fatty liver graft preservation: a role for melatonin and trimetazidine cocktail
Zaouali MA, et al.
Journal of Pineal Research, 55(1), 65-78 (2013)
Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds.
P W Krug et al.
Antimicrobial agents and chemotherapy, 54(1), 452-459 (2009-10-28)
B virus infection of humans results in high morbidity and mortality in as many as 80% of identified cases. The main objective of this study was to conduct a comparative analysis of conventional and experimental antiviral drug susceptibilities of B
Budiman Kharma et al.
International journal of cancer, 133(9), 2234-2244 (2013-04-19)
Endometrial cancer, one of the most common gynecologic malignancies, is increasing in Japan, nearly doubling over the last decade. High-grade disease patients are often resistant to conventional chemotherapy with platinum agents; therefore, discovery of efficacious new drugs in this setting
Satoko Koteda et al.
[Rinsho ketsueki] The Japanese journal of clinical hematology, 54(3), 311-315 (2013-05-17)
A 62-year-old woman with acute lymphoblastic leukemia in first complete remission was treated with unrelated cord blood transplantation, but exhibited primary graft failure. She then underwent HLA-haploidentical peripheral blood stem cell transplantation from her daughter. The conditioning regimen consisted of
Chun-Hao Tsai et al.
Oncotarget, 6(1), 258-270 (2014-11-19)
Resistin is a recently discovered adipocyte-secreting adipokine, which may play a critical role in modulating cancer pathogenesis. Chondrosarcoma is a highly malignant tumor known to frequently metastasize; however, the role of resistin in the metastasis of human chondrosarcoma is largely
Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL).
Brian T Hill et al.
British journal of haematology, 164(2), 297-299 (2013-10-18)
Issa F Khouri et al.
Blood, 124(14), 2306-2312 (2014-08-26)
Myelosuppression, graft-versus-host disease (GVHD), and relapse remain major causes of morbidity after stem cell transplantation for relapsed lymphoma. In this phase 1/2 study, we tested the safety and efficacy of escalating doses of bendamustine (70, 90, 110, and 130 mg/m2
Sacha Satram-Hoang et al.
Annals of hematology, 93(8), 1335-1344 (2014-03-19)
The median age at diagnosis of chronic lymphocytic leukemia (CLL) is 72, but patients enrolled in randomized trials are often a decade younger. Therapy selection and outcomes in the older, comorbid population are less understood. We evaluated treatment patterns and
Yoshinobu Kanda et al.
American journal of hematology, 88(4), 294-300 (2013-03-02)
We evaluated the efficacy of in vivo T-cell depletion with alemtuzumab in two prospective studies according to the International Conference on Harmonisation (ICH)-Good Clinical Practice (ICH-GCP) guidelines; one was for patients with aplastic anemia (AA study) and the other was
Nicolas Novitzky et al.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 19(4), 584-588 (2012-12-29)
Immunodepletion with alemtuzumab is an effective strategy for preventing graft-versus-host disease after allogeneic stem cell transplantation (SCT), but it may be associated with graft failure. We tested the effectiveness of a purine analog-based reduced-intensity conditioning combination in patients undergoing allogeneic
Alessandro Gozzetti et al.
Leukemia research, 38(8), 891-895 (2014-06-18)
Median age at diagnosis for chronic lymphocytic leukaemia (CLL) patients is now 72 years, thus a consistent number of patients may not tolerate standard doses i.v. of fludarabine, cyclophosphamide and rituximab (FCR), the best available therapy, due to unacceptable myelotoxicity
Dario Ferrero et al.
Annals of hematology, 93(8), 1391-1400 (2014-04-08)
We evaluated a maintenance, post-remission treatment with low-dose chemotherapy plus differentiating agents on poor-prognosis acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) patients ineligible to allografting. Patients had either age over 60 and/or secondary AML, therapy-related AML, previous relapse, high-risk MDS. Forty-five
Joshua Lukenbill et al.
Leukemia research, 37(9), 986-994 (2013-06-22)
Fludarabine successfully treats chronic lymphocytic leukemia (CLL); however, its use may lead to significant myelosuppression and other toxicities. This article weighs the benefits against potential harms, highlighting strategies for appropriate patient selection and administration. Relevant studies were identified upon literature
Muhammad Rizwan Khawaja et al.
American journal of hematology, 90(2), 97-99 (2014-10-28)
We compared survival outcomes following myeloablative allotransplant (MAT) or cyclophosphamide/fludarabine (Cy/Flu) nonmyeloablative allotransplant (NMAT) for 165 patients with acute myelogenous leukemia (AML) in remission or without frank relapse. Patients who received NMAT were more likely to be older and have
Georg Hopfinger et al.
Cancer, 119(12), 2258-2267 (2013-03-21)
Scarce systematic trial data have prevented uniform therapeutic guidelines for T-cell prolymphocytic leukemia (T-PLL). A central need in this historically refractory tumor is the controlled evaluation of multiagent chemotherapy and its combination with the currently most active single agent, alemtuzumab.
HLA-matched related-donor HSCT in Fanconi anemia patients conditioned with cyclophosphamide and fludarabine.
Lina Benajiba et al.
Blood, 125(2), 417-418 (2015-01-13)
Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease.
Kavita Radhakrishnan et al.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 19(4), 676-677 (2013-02-14)
Jakub Bogusz et al.
Postepy higieny i medycyny doswiadczalnej (Online), 67, 107-118 (2013-03-12)
Chronic lymphocytic leukemia (CLL) remains incurable; therefore searching for new therapeutic strategies in this disease is necessary. An important mechanism of tumor development is neoangiogenesis. A potent antiangiogenic factor, bevacizumab (Avastin, AVA), has been poorly explored in CLL so far.
Wenjun Zhang et al.
Medicine, 93(27), e134-e134 (2014-12-17)
This retrospective study compared efficacy and safety of fludarabine combined with intermediate-dose cytarabine (FA regimen) versus high-dose cytarabine (HiDAC regimen) as consolidation therapy in acute myeloid leukemia (AML) patients who achieved complete remission. Disease-free survival (DFS) and overall survival (OS)
Erik C Gunther et al.
Cell reports, 26(1), 145-158 (2019-01-04)
Cellular prion protein (PrPC) binds the scrapie conformation of PrP (PrPSc) and oligomeric β-amyloid peptide (Aβo) to mediate transmissible spongiform encephalopathy (TSE) and Alzheimer's disease (AD), respectively. We conducted cellular and biochemical screens for compounds blocking PrPC interaction with Aβo.
Wolfgang Dörffel et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(12), 1562-1568 (2013-03-20)
PURPOSE To minimize the risk of late effects in pediatric Hodgkin lymphoma (HL) by omitting radiotherapy (RT) in patients in complete remission (CR) after chemotherapy and reducing the standard radiation dose to 20 Gy in patients in incomplete remission. Between
1/4